Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858246 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2AOPRK1MEN1L3MBTL1 | |
| SCHEMBL6903617 | 0.89 | MAPT (0.52) | SMN1; SMN2KMT2AMEN1POLBTHRA | |
| SCHEMBL6863511 | 0.86 | THRA (0.43) | OPRK1THRATHRB | |
| SCHEMBL6862542 | 0.85 | MTNR1A (0.43) | SMN1; SMN2KMT2AOPRK1MEN1L3MBTL1 | |
| SCHEMBL6898600 | 0.82 | RAB9A (0.43) | SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL6863788 | 0.78 | GAA (0.42) | SMN1; SMN2OPRK1POLBALDH1A1GAA | |
| SCHEMBL18918559 | 0.78 | THRB (0.48) | SMN1; SMN2THRATHRB | |
| SCHEMBL6904592 | 0.76 | CA2 (0.38) | SMN1; SMN2KMT2APOLBALDH1A1GAA | |
| SCHEMBL3149063 | 0.75 | MGLL (0.46) | SMN1; SMN2KMT2AOPRK1MEN1L3MBTL1 | |
| SCHEMBL3158226 | 0.73 | PPARA (0.41) | THRATHRBALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803480-B2 | THERAPEUTIC TREATMENT AND/OR PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-10-12 | — | — | US | disclosed |
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | APOB, HMGCR, PCSK9 | SMN1; SMN2 4560/4885KMT2A 1345/4885OPRK1 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.